SUNREST Peer Comparison

NSE: SUNREST

₹39.60

₹1.60 (4.21%)

As on 28-Aug-2026IST

Market cap

₹34 Cr

Revenue (TTM)

₹71 Cr

P/E Ratio

8.3

P/B Ratio

1

Div. Yield

0 %

Edit

	SUNREST	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	34	35,497	29,798	16,589	15,507
Revenue (₹ Cr)	71	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	7.99	1,018.97	497.77	603.02	270.18
Net Margin (%)	10.90	10.47	20.72	22.63	23.29
RoE (%)	43.52	21.30	28.49	19.61	14.45
Price to Earnings	8.26	35.10	59.86	27.51	56.31
Price-To-Book	0.96	6.77	14.74	4.76	7.48

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	SUNREST	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	70.83	9,203.54	2,022.99	2,551.83	1,054.89
Total Income	73.34	9,335.01	2,053.15	2,612.24	1,107.25
Total Expenditure	60.63	7,457.80	1,448.49	1,754.55	686.95
EBITDA	10.21	1,745.74	574.50	797.28	367.94
Depreciation	1.19	415.05	91.74	75.36	74.46
EBIT	9.01	1,330.70	482.76	721.93	293.48
Interest	1.42	143.67	23.95	5.37	0.82
Other Income	2.51	131.47	30.17	60.41	52.36
Exceptional Items	--	-31.35	--	-25.66	-3.28
Profit before Tax	10.10	1,287.14	488.98	751.31	344.65
Provision for Tax	2.11	345.87	124.98	186.83	85.42
Profit after Tax	7.99	941.27	364.00	564.48	259.23

Liabilities (₹ Cr)

	SUNREST	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	20.43	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	9.20	26.64	--	--	-1.92
Non-Current Liabilities	11.96	584.19	345.47	142.73	47.58
Current Liabilities	29.46	3,912.24	710.20	682.24	169.08
Total Liabilities	71.41	9,514.48	2,930.14	4,157.10	2,231.79

Assets (₹ Cr)

	SUNREST	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	8.58	3,861.01	1,447.01	1,333.54	981.68
Current Assets	62.47	5,612.10	1,483.13	2,823.56	1,250.11
Total Assets	71.41	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	17.46	1,204.08	196.61	0.00	0.00
Net Current Assets	33.01	1,699.86	772.93	2,141.33	1,081.03
Contingent Liabilities	0.02	258.92	13.18	4.82	3.76

Cashflow (₹ Cr)

	SUNREST	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-0.05	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-2.91	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	3.99	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	1.03	93.92	-56.08	-69.08	11.28

Ratios

Profitability Ratios

	SUNREST	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	34.78	25.25	27.50	24.61	18.04
ROE (%)	43.52	20.09	21.43	18.41	13.54
ROA (%)	12.37	10.70	14.25	14.27	12.15
EBIT Margin (%)	17.95	20.40	29.89	33.61	39.84
Net Margin (%)	10.90	10.08	17.73	21.61	23.41
Cash Profit Margin (%)	12.97	14.44	22.53	24.81	31.63

Growth Ratios

	SUNREST	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	111.99	16.56	36.98	6.91	-12.10
EBIT Growth (%)	320.43	21.77	75.89	19.60	-23.76
Net Profit Growth (%)	297.61	33.05	39.94	16.24	-30.25
EPS Growth (%)	105.27	35.59	39.94	16.05	-29.80
Book Value Growth (%)	25.24	11.36	22.95	18.43	11.27

Valuation Ratios

	SUNREST	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	3.60	32.73	42.34	21.18	40.73
Price / Book Value	0.72	6.13	8.23	3.60	5.27
Dividend Yield (%)	0.00	0.23	0.28	0.51	0.74
EV/EBITDA	2.40	16.68	25.23	13.94	25.25
Market Cap (₹ Cr)	15.88	30,257.56	15,412.11	11,956.86	10,627.92

Solvency Ratios

	SUNREST	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.85	0.24	0.10	0.00	0.00
Short term debt to equity ratio	0.25	0.16	--	--	--
Current Ratio	2.12	1.43	2.09	4.14	7.39
Quick Ratio	1.54	0.82	1.37	3.12	5.46
Interest Coverage	8.12	9.96	21.42	140.86	419.57

Operating Efficiency Ratios

	SUNREST	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	45.83	27.84	26.76	42.05	43.63
Asset Turnover	1.10	1.07	0.79	0.65	0.49
Receivable days	177.34	88.68	77.32	144.58	169.86
Inventory Days	68.75	84.11	80.83	96.67	97.92
Payable days	181.27	176.65	125.94	135.45	159.68
Cash Conversion Cycle	64.82	-3.86	32.22	105.80	108.11